{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T16:39:34Z","timestamp":1792687174757,"version":"4.5.0"},"reference-count":0,"publisher":"S. Karger AG","license":[{"start":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T00:00:00Z","timestamp":1792540800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T00:00:00Z","timestamp":1792540800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cardiorenal Med"],"abstract":"<jats:p>Background: Cardiorenal disease emerges from reciprocal injury among the heart, vasculature, kidney, and metabolic organs, with maladaptive neurohormonal activation as a central pathobiological driver. Although renin-angiotensin-aldosterone system (RAAS) blockade has transformed cardiorenal care, substantial residual risk persists despite contemporary multidrug therapy, including mineralocorticoid receptor antagonists and sodium-glucose cotransporter 2 inhibitors Objective and scope: This review summarizes mechanistic and translational evidence linking apelin\/APJ signaling to RAAS regulation in cardiorenal disease, with emphasis on APJ-AT1R interaction, ACE2\/Ang-(1-7)\/Mas signaling, endothelial and metabolic protection, autophagy, inflammatory-fibrotic remodeling, apelin resistance, and emerging APJ agonists. Conclusions: Current evidence supports the apelin\/APJ system as a compensatory cardiorenal network that may complement, rather than replace, evidence-based RAAS-directed therapy. Future studies should move beyond descriptive associations toward standardized apelin\/Elabela assays, phenotype-specific disease models, combination-treatment experiments, and early clinical trials with renal, cardiovascular, biomarker, congestion, and safety endpoints.<\/jats:p>","DOI":"10.1159\/crm\/abtag017","type":"journal-article","created":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T11:20:44Z","timestamp":1792408844000},"source":"Crossref","is-referenced-by-count":0,"title":["The apelin\/APJ system as a complementary target to RAAS blockade in cardiorenal disease"],"prefix":"10.1159","author":[{"given":"Liya","family":"Lin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanxiao","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingyue","family":"Jia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoxiao","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"127","published-online":{"date-parts":[[2026,10,21]]},"container-title":["Cardiorenal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/karger.com\/article-pdf\/doi\/10.1159\/crm\/abtag017","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T16:01:28Z","timestamp":1792684888000},"score":1,"resource":{"primary":{"URL":"https:\/\/karger.com\/article\/doi\/10.1159\/crm\/abtag017"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,21]]},"references-count":0,"URL":"https:\/\/doi.org\/10.1159\/crm\/abtag017","archive":["Portico"],"relation":{},"ISSN":["1664-3828","1664-5502"],"issn-type":[{"value":"1664-3828","type":"print"},{"value":"1664-5502","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,21]]}}}